Genetesis, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2013-09-05
- Employees
- 11
- Market Cap
- -
- Website
- http://www.genetesis.com
Clinical Trials
13
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)
- Conditions
- Myocardial IschemiaIschemic Heart DiseaseAnginaCoronary Microvascular Disease
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Genetesis Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT06212466
- Locations
- 🇺🇸
University of Florida, Division of Cardiovascular Medicine, Gainesville, Florida, United States
🇺🇸Saint Elizabeth Medical Center, Edgewood, Kentucky, United States
🇺🇸Ascension St. John Hospital, Detroit, Michigan, United States
MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR
- Conditions
- AnginaIschemic Heart DiseaseCoronary Microvascular Disease
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Genetesis Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT06139094
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸Ascension St. John Hospital, Detroit, Michigan, United States
🇺🇸The Christ Hospital, Cincinnati, Ohio, United States
A Registry of Cardiac PET and CardioFlux Magnetocardiography in Patients with Suspected Coronary Ischemia.
- Conditions
- Coronary; Ischemic
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Genetesis Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT05868902
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Kettering Health, Kettering, Ohio, United States
Magnetocardiography as a Noninvasive Diagnostic Strategy for Identifying Coronary Allograft Vasculopathy
- Conditions
- Coronary Allograft Vasculopathy (CAV)
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Genetesis Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05751915
- Locations
- 🇺🇸
The Cleveland Clinic, Cleveland, Ohio, United States
MCG as a Noninvasive Diagnostic Strategy for Suspected Coronary Microvascular Dysfunction
- Conditions
- Ischemic Non-Obstructive Coronary Artery DiseaseCoronary Microvascular Dysfunction
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Genetesis Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT05150054
- Locations
- 🇺🇸
Ascension St. John, Detroit, Michigan, United States
🇺🇸The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
- Prev
- 1
- 2
- 3
- Next